InVision® platform
Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients
InVisionFirst®Lung
Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients
Radar™
A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform
Our Mission
We are transforming the lives of cancer patients and their families through the power of liquid biopsy
Latest News and Events
US Commercial Launch of InVisionFirst®-Lung
Inivata’s Liquid Biopsy Test for Advanced Non-Small Cell Lung Cancer is Now Available Through NeoGenomics in the US Read More
Circulating tumor DNA genomics reveals potential mechanisms of resistance to BRAF-targeted therapies in BRAF-mutant metastatic non-small cell lung cancer patients
Sandra Ortiz-Cuaran, Laura Mezquita, Aurélie Swalduz, Mihaela Aldea, Julien Mazieres, Camille Leonce, Cecile Jovelet, Anne Pradines, ... Read More
Changing Lives
Patients are at the heart of everything we do.
Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives.
This is the story of the first patient Inivata tested.
